1 September 2024
Appendix 4C - Quarterly Cashflow Report
Melbourne, Australia; 28 July 2011 – Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today released its Appendix 4C – Quarterly Cash Flow Report for the period ended 30 June 2011.
The net cash burn for the year was $3.9m, resulting in a cash balance of $18.9m at 30 June 2011.
The total operating and investing cash outflow for the quarter was $1.2m and the total for the financial year to 30 June 2011 was $6.7m. This included costs for the recently completed Phase 2 clinical trial that demonstrated efficacy of VivaGel® as a treatment for bacterial vaginosis. Financing cash inflows of $3.6m resulted from the exercise of share options during the year. Receipts from customers included royalty, license and research income from the Company’s growing list of partners.
Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report